Sign in
4

Changes in Ownership

Acrivon Therapeutics, Inc. Filed Acc 0001209191-22-057398

Chief Financial Officer acquired 20,030 shares (grant or award)

From the SEC's structured data for this filing

Trades in this filing

Holm-Jorgensen Rasmus · Chief Financial Officer

Table I: Non-derivative

1 line
Date Transaction Shares Owned after D/I
2022-11-14 Grant or award : show line 1 in the form +20,030 20,030 D

Table II: Derivative

1 line
Date Transaction Shares Owned after D/I
2022-11-14 Grant or award : show line 2 in the form Stock Option (Right to Buy) +60,090 60,090 D
Loading xslF345X03/doc4.xml…